Aldeyra Therapeutics Inc ALDX.OQ ALDX.O is expected to show a rise in quarterly revenue when it reports results on February 26 (estimated) for the period ending December 31 2025
The Lexington Massachusetts-based company is expected to report revenue of $24.25 million, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Aldeyra Therapeutics Inc is for a loss of 17 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Aldeyra Therapeutics Inc is $9.50, about 90.4% above its last closing price of $4.99
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.20 | -0.24 | -0.13 | Beat | 46.9 |
Jun. 30 2025 | -0.23 | -0.24 | -0.16 | Beat | 34.2 |
Mar. 31 2025 | -0.30 | -0.28 | -0.17 | Beat | 39.3 |
Dec. 31 2024 | -0.26 | -0.23 | -0.27 | Missed | -19.9 |
Sep. 30 2024 | -0.26 | -0.25 | -0.25 | Met | -1.2 |
Jun. 30 2024 | -0.14 | -0.14 | -0.28 | Missed | -97.5 |
Mar. 31 2024 | -0.10 | -0.11 | -0.14 | Missed | -26.5 |
Dec. 31 2023 | -0.05 | -0.14 | -0.08 | Beat | 43 |
This summary was machine generated February 24 at 21:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments